| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444063 | European Journal of Cancer | 2013 | 9 Pages |
Abstract
With a higher cumulative dose for the concurrent arm, no differences were observed between the two treatment arms with respect to pCR rate. The differential toxicity profile could partly be explained by different use of primary G-CSF prophylaxis.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
B.E.P.J. Vriens, M.J.B. Aarts, B. de Vries, S.M. van Gastel, J. Wals, T.J. Smilde, L.J.C. van Warmerdam, M. de Boer, D.J. van Spronsen, G.F. Borm, V.C.G. Tjan-Heijnen,